Evusheld

Department of Health and Social Care written question – answered on 27th June 2022.

Alert me about debates like this

Photo of Daisy Cooper Daisy Cooper Liberal Democrat Spokesperson (Health and Social Care)

To ask the Secretary of State for Health and Social Care, with reference to the Answer of 20 April 2022 to Question 151279, on Evusheld, whether the UKHSA has reviewed studies published by the US Food and Drug Administration and European Medicines Agency on the effectiveness of Evusheld against the covid-19 omicron variant; and for what reason the UKHSA has decided to undertake duplicate studies on the effectiveness of that drug.

Photo of Maggie Throup Maggie Throup The Parliamentary Under-Secretary for Health and Social Care

The UK Health Security Agency has been commissioned by AstraZeneca to undertake specific testing on the efficacy of Evusheld and therefore has no plans to review external studies. UKHSA began the process of testing against the Omicron variant in March 2022. Following the completion of preliminary laboratory work, such testing lasts for approximately three to four weeks. The data gathered will be considered by expert clinical groups with other available information, which will inform any potential procurement decisions.

Does this answer the above question?

Yes3 people think so

No37 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.